European Association for Haemophilia and Allied Disorders

What European Association for Haemophilia and Allied Disorders does

The European Association for Haemophilia and Allied Disorders (EAHAD) is a non-profit professional medical association founded in 2007 and headquartered in Brussels, Belgium. It serves multidisciplinary healthcare professionals—including haematologists, nurses, physiotherapists, psychosocial specialists, laboratory scientists, and researchers—engaged in the care of individuals with haemophilia and other bleeding disorders across Europe. Its operational scope spans education, clinical guideline development, research funding, pharmacovigilance, and advocacy.

EAHAD's core product portfolio centers on the EAHAD Academy e-learning platform (powered by MULTILEARNING's LMS), which delivers 24+ structured modules, gene therapy webinars, podcasts, and live events, complemented by the annual EAHAD Congress drawing nearly 2,200 delegates from 78+ countries. Specialized assets include the Gene Therapy Trials Database, the Coagulation Factor Variant Databases, the EUHASS pharmacovigilance system, the European Haemophilia Centres Accreditation program, and a portfolio of research grants and clinical guidelines. The association is governed by an Executive Committee plus discipline-specific committees (Nurses, Physiotherapists, Psychosocial Professionals) and condition-specific working groups (Gene Therapy, Von Willebrand Disease, Glanzmann Thrombasthenia, Very Rare Coagulation Factor Deficiencies, and others), and it maintains formal MoUs with the International Society on Thrombosis and Haemostasis (ISTH), the World Federation of Hemophilia (WFH), and the European Haemophilia Consortium (EHC).

EAHAD generates revenue through three primary streams: recurring membership dues, annual congress registration fees, and corporate partnerships and sponsorships with pharmaceutical companies. Its go-to-market is community-led, with members acquired and retained through congress attendance, committee participation, working group involvement, and enrollment in accredited e-learning programs. The organization does not disclose revenue, has no external funding rounds as a non-profit, and operates with a small (1-10) staff supported by elected volunteer leadership on a rotating two-year presidential cycle.

Name

European Association for Haemophilia and Allied Disorders

Legal name

European Association for Haemophilia and Allied Disorders

Website

https://eahad.org

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

EAHAD is a Brussels-based non-profit professional association, founded in 2007, that serves multidisciplinary European healthcare professionals in haemophilia and bleeding disorders through education, an annual congress, e-learning, research grants, and clinical standards.

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Dues: EAHAD generates revenue through membership fees, providing members exclusive benefits including Congress discounts and educational resources access.
2. Congress Registration Fees: The annual EAHAD Congress attracts nearly 2,200 delegates from over 78 countries, generating revenue through registration fees. The congress includes satellite symposia and partnership events.
3. Corporate Partnerships and Sponsorships: EAHAD maintains a Corporate Partners program and collaborates with pharmaceutical companies for congress symposia, educational modules, and research initiatives.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels10 records

Core offering

EAHAD is a multidisciplinary professional association that delivers continuing education, an annual congress, e-learning modules, gene therapy webinars, a podcast, research grants, centre accreditation, and clinical and pharmacovigilance databases (EUHASS, Coagulation Factor Variant Database, Gene Therapy Trials Database) to healthcare professionals working in haemophilia and allied bleeding disorders across Europe.

Product overview

EAHAD is a multidisciplinary association offering a unified portfolio of educational products and services for healthcare professionals in haemophilia and bleeding disorders care. The core offering centers on the EAHAD Academy e-learning platform, which delivers 24+ structured E-Learning Modules and Gene Therapy Webinars, complemented by a Podcast series and live educational events. The organization hosts the Annual EAHAD Congress as its flagship conference, while supporting the field through Research Grants, a European Haemophilia Centres Accreditation program, and specialized Professional Networks for nurses, physiotherapists, and psychosocial professionals. Technical resources include the Coagulation Factor Variant Databases and Gene Therapy Trials Database, managed by dedicated Working Groups.

Differentiator

Problem solved

Functional benefit

Brands

• EAHAD Academy: The online learning platform providing e-learning modules, webinars, interviews, and educational content for healthcare professionals in haemophilia and bleeding disorders care.

Products and services

• EAHAD Academy Online e-learning platform delivering multidisciplinary continuing education modules, courses, and resources for healthcare professionals working in haemophilia and allied bleeding disorders across Europe.
• EAHAD Annual Congress Annual multidisciplinary congress convening haematologists, nurses, physiotherapists, psychosocial care providers, and laboratory scientists to present research, share clinical practice, and discuss emerging therapies in haemophilia and allied bleeding disorders.
• Gene Therapy Webinars Educational webinar series focused on gene therapy advances, clinical trial updates, and clinical implementation guidance for haemophilia and bleeding disorders care.
• EAHAD Podcast Podcast channel providing on-demand audio content on haemophilia and allied bleeding disorders topics for multidisciplinary clinician audiences.
• EAHAD Research Grants Competitive research grant funding programme supporting clinical and translational research projects in haemophilia and allied bleeding disorders undertaken by healthcare professionals and researchers.
• European Haemophilia Centres Accreditation Formal accreditation programme that recognises and certifies European haemophilia treatment centres that meet EAHAD's defined multidisciplinary standards of clinical care for bleeding disorders.
• Coagulation Factor Variant Databases Curated clinical databases cataloguing genetic variants and mutations affecting coagulation factors, supporting diagnostic interpretation and research in haemophilia and allied bleeding disorders.
• European Haemophilia Safety Surveillance (EUHASS) Pan-European pharmacovigilance and adverse-event surveillance registry operated by EAHAD that monitors safety signals across participating haemophilia treatment centres.
• Gene Therapy Trials Database Curated database tracking ongoing and completed gene therapy clinical trials in haemophilia, supporting clinician awareness and research planning.
• EAHAD Professional Networks, Committees, and Working Groups Standing committees, working groups, and professional networks that coordinate multidisciplinary collaboration across haematology, nursing, physiotherapy, psychosocial care, and laboratory science within the European bleeding disorders community.

Quantifiable outcome

• Nearly 2,200 delegates from 78+ countries attend the annual EAHAD Congress
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• European Haemophilia Consortium (EHC)coreStrategic or Co-development Partner · 3 July 2026EAHAD collaborates extensively with EHC on gene therapy implementation, developing the hub and spoke model for haemophilia gene therapy. EHC patient representatives participate in the EAHAD Gene Therapy Working Group. The organizations co-host events including the EHC Conference 2026 listed on EAHAD's events page.
• World Federation of Hemophilia (WFH)coreStrategic or Co-development Partner · 4 October 2025EAHAD and WFH signed a Memorandum of Understanding (MoU) in October 2025 to formalize collaboration on haemophilia advocacy, education, and treatment access initiatives. The partnership includes collaborative efforts between professional committees such as the Nurses Committees of both organizations.
• International Society on Thrombosis and Haemostasis (ISTH)coreStrategic or Co-development Partner · 22 June 2025EAHAD and ISTH signed a Memorandum of Understanding (MoU) in June 2025 to strengthen collaboration between the two organizations. The partnership includes joint sessions at congresses, such as the EAHAD-ISTH Joint Session on Novel Therapies, and collaborative advocacy efforts including a Call-to-Action on haemophilia treatment sustainability.
• EMJ (European Medical Journal)minorGTM or Marketing PartnerEMJ is listed as a Media Partner of EAHAD, providing media coverage and content distribution for the organization's activities and congress.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• International Society on Thrombosis and Haemostasis (ISTH): Global professional society for thrombosis and haemostasis researchers and clinicians. Direct peer — overlapping scientific congress, educational content, and guideline-setting role; subject of EAHAD's June 2025 MoU and joint Novel Therapies sessions.
• World Federation of Hemophilia (WFH): Global haemophilia patient and treatment-access organisation. Direct peer on advocacy, education, and congress collaboration; EAHAD signed an MoU with WFH in October 2025 covering Nurses Committee collaboration and treatment-access initiatives.
• Hemostasis and Thrombosis Research Society (HTRS): North American clinician-led society focused on hemostasis and thrombosis research and education. Direct peer in mission (specialty education, research grants, annual scientific meeting), serving a parallel continental audience to EAHAD's European base.
• European Haemophilia Consortium (EHC): European patient-advocacy umbrella for national haemophilia societies. Direct collaborator — jointly built the hub-and-spoke gene therapy delivery model, co-hosts events, and has EHC patient representatives on EAHAD's Gene Therapy Working Group.

Emerging players

• International Society of Blood Transfusion (ISBT): Global society on transfusion medicine with adjacency to bleeding-disorders care. Partial overlap via transfusion-science education and shared clinician audiences relevant to comprehensive haemophilia treatment centres.

Broad incumbents

• American Society of Hematology (ASH): Largest global haematology professional society with comparable educational products (Hematology Education Program, CME, guideline-setting). Competes for member mindshare and congress attendance; broader than EAHAD but overlapping on bleeding disorders programming.
• European Hematology Association (EHA): European haematology umbrella society covering all blood disorders — broader but overlapping on educational content, congresses, and CME accreditation. EAHAD's multidisciplinary model differentiates within EHA's wider scope.

Regional players

• National Hemophilia Foundation (NHF): US national haemophilia advocacy and education organisation. Comparable in mission and educational programming; primarily serves North America but operates bleeding-disorders education and training parallel to EAHAD.
• British Society for Haematology (BSH): UK professional society for haematology with overlapping educational and guideline activity in bleeding disorders. Regional peer serving UK clinicians, comparable to EAHAD's professional-society and education role within Europe.

Others

• European Medical Journal (EMJ): Medical publisher and media partner with EAHAD congress coverage. Adjacent enabling relationship (media distribution) rather than competing association; comparable to other content-distribution partners in the medical-education ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/EAHADnews
• YouTubeyoutube.com/@eahad_education
• LinkedInlinkedin.com/company/european-association-for-haemophilia-and-allied-disorders

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Association for Haemophilia and Allied Disorders